Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines

C.M.M. van Geelen, E.G.E. de Vries, T.K.P. Le, R.P. van Weeghel, S. de Jong

    Research output: Contribution to journalArticleAcademicpeer-review

    51 Citations (Scopus)
    194 Downloads (Pure)

    Abstract

    Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and CD95 ligand (CD95L) are potent inducers of apoptosis in various tumour cell types. Death receptors DR4 and DR5 can induce and decoy receptors DcR1 and DcR2 can inhibit TRAIL-mediated apoptosis. The study aim was to investigate whether anticancer agents can modulate similarly TRAIL-receptor and CD95 membrane expression and TRAIL and CD95L sensitivity.Three colon carcinoma cell lines (Caco-2, Colo320 and SW948) were treated with 5-fluorouracil (5-FU), cisplatin or interferon-γ. TRAIL-receptor and CD95 membrane expression was determined flow cytometrically. Sensitivity to TRAIL or CD95L agonistic anti-CD95 antibody was determined with cytotoxicity and apoptosis assays. SW948 showed highest TRAIL sensitivity. The protein synthesis inhibitor cycloheximide decreased FLICE-like inhibitory protein levels in all cell lines, and the TRAIL-resistant cell lines Caco-2 and Colo320 became sensitive for TRAIL. Exposure of the cell lines to 5-FU, cisplatin and interferon-γ left TRAIL-receptor membrane expression and TRAIL sensitivity unaffected. CD95 membrane expression and anti-CD95 sensitivity was, however, modulated by the same drugs in all lines. Cisplatin and interferon-γ raised CD95 membrane levels 6–8-fold, interferon-γ also increased anti-CD95 sensitivity. These results indicate that the CD95 and TRAIL pathways use different mechanisms to respond to various anticancer agents. Induced CD95 membrane upregulation was associated with increased anti-CD95 sensitivity, whereas no upregulation of TRAIL-receptor membrane expression or TRAIL sensitisation could be established. For optimal use of TRAIL-mediated apoptosis for cancer therapy in certain tumours, downregulation of intracellular inhibiting factors may be required.
    Original languageEnglish
    Pages (from-to)363 - 373
    Number of pages11
    JournalBritish Jounal of Cancer
    Volume89
    Issue number2
    DOIs
    Publication statusPublished - Jul-2003

    Keywords

    • TRAIL
    • TRAIL receptors
    • CD95
    • apoptosis
    • colon carcinoma
    • APOPTOSIS-INDUCING LIGAND
    • NECROSIS-FACTOR-ALPHA
    • HUMAN-MELANOMA CELLS
    • MEDIATED APOPTOSIS
    • ANTITUMOR-ACTIVITY
    • CANCER-CELLS
    • INTRACELLULAR REGULATION
    • DECOY RECEPTORS
    • GENE-EXPRESSION
    • APO-2 LIGAND

    Cite this